{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:07:04Z","timestamp":1792688824246,"version":"4.5.0"},"reference-count":27,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2017,7,6]]},"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of an extemporaneous preparation of 2% ganciclovir topical eye drops in cytomegalovirus (CMV) anterior uveitis because many studies have confirmed the benefits of topical ganciclovir in varying concentrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>The study employed a retrospective cohort design.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study enrolled 11 eyes (11 patients) with CMV anterior uveitis. All cases were proved by positive PCR for CMV DNA from aqueous tapping and received topical 2% ganciclovir, applied every 2\u2009hours daily as induction therapy then tapered off and stopped based on clinical response. Outcome measures were best-corrected visual acuity, anterior chamber cell, coin-shaped and other keratic precipitates, intraocular pressure (IOP), the number of antiglaucoma drugs used, the frequency of steroid eye drops used daily and side effects over a 12-month follow-up period. Side effects after applying topical 2% ganciclovir were recorded using questionnaires and eye examination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean age was 49.0\u00b117.8 years. IOP, number of antiglaucoma drugs used and keratic precipitates decreased significantly at first week (p&lt;0.013, p&lt;0.024 and p&lt;0.031, respectively) followed by decreased anterior chamber cells and significantly reduced frequency of applying steroid eye drops at 4\u2009weeks (p&lt;0.034 and p&lt;0.017, respectively). Visual acuity significantly improved at 5\u2009months continuously. All clinical improvement was maintained to 12 months, and keratic precipitates were eliminated in 90% of all cases. However, in 27% of discontinued medicine cases, inflammation was recurrent. No significance was observed in all factors between recurrent and non-recurrent groups. The most common side effect was eye irritation (27.27%). No severe complications from the medicine was detected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Extemporaneous preparation topical 2% ganciclovir was effective and safely controlled CMV anterior uveitis. The medication is non-invasive, economical and convenient for hospitals where commercial topical ganciclovir is unavailable.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2016-000061","type":"journal-article","created":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T20:50:29Z","timestamp":1504817429000},"page":"e000061","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and safety of an extemporaneous preparation of 2% ganciclovir eye drops in CMV anterior uveitis"],"prefix":"10.1136","volume":"2","author":[{"given":"Narumon","family":"Keorochana","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Phramongkutklao hospital, Phramongkutklao College of Medicine, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveewan","family":"Choontanom","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Phramongkutklao hospital, Phramongkutklao College of Medicine, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,7]]},"reference":[{"key":"2025090109363951000_2.1.e000061.1","unstructured":"Skuta GL , Cantor LB , Weiss JS . Basic and clinical science Course 2012-2013: intraocular inflammation and uveitis. 77. Canada: American Academy of Ophthalmology, 2012."},{"key":"2025090109363951000_2.1.e000061.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.04.053"},{"key":"2025090109363951000_2.1.e000061.3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.4314\/ahs.v15i3.7","article-title":"Polymerase chain reaction to search for Herpes viruses in uveitic and healthy eyes: a South African perspective","volume":"15","author":"Laaks","year":"2015","journal-title":"Afr Health Sci"},{"key":"2025090109363951000_2.1.e000061.4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1590\/S0004-27492011000400006","article-title":"Real-time PCR in infectious uveitis as an alternative diagnosis","volume":"74","author":"Santos","year":"2011","journal-title":"Arq Bras Oftalmol"},{"key":"2025090109363951000_2.1.e000061.5","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2014.950384"},{"key":"2025090109363951000_2.1.e000061.6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12348-016-0100-5","article-title":"Cytomegalovirus as a cause of hypertensive anterior uveitis in immunocompetent patients","volume":"6","author":"Choi","year":"2016","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2025090109363951000_2.1.e000061.7","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00417-014-2844-7","article-title":"Erratum to: Cytomegalovirus anterior uveitis: long-term follow-up of immunocompetent patients","volume":"252","author":"Accorinti","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025090109363951000_2.1.e000061.8","doi-asserted-by":"publisher","DOI":"10.1007\/BF00136737"},{"key":"2025090109363951000_2.1.e000061.9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701757"},{"key":"2025090109363951000_2.1.e000061.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)00961-2"},{"key":"2025090109363951000_2.1.e000061.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.12.015"},{"key":"2025090109363951000_2.1.e000061.12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-3-0348-8012-1_8","article-title":"Current and potential therapies for the treatment of herpes-virus infections","volume":"60","author":"Villarreal","year":"2003","journal-title":"Prog Drug Res"},{"key":"2025090109363951000_2.1.e000061.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.086546"},{"key":"2025090109363951000_2.1.e000061.14","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304625"},{"key":"2025090109363951000_2.1.e000061.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609053351007"},{"key":"2025090109363951000_2.1.e000061.16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3341\/kjo.2013.27.2.130","article-title":"A case of CMV endotheliitis treated with intravitreal ganciclovir injection","volume":"27","author":"Choi","year":"2013","journal-title":"Korean J Ophthalmol"},{"key":"2025090109363951000_2.1.e000061.17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12348-016-0078-z","article-title":"Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis","volume":"6","author":"Wong","year":"2016","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2025090109363951000_2.1.e000061.18","doi-asserted-by":"crossref","unstructured":"Koizumi N , Miyazaki D , Inoue T , et al . The effect of topical application of 0.15% ganciclovir gel on Cytomegalovirus corneal endotheliitis. Br J Ophthalmol 2016.","DOI":"10.1136\/bjophthalmol-2015-308238"},{"key":"2025090109363951000_2.1.e000061.19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/ICO.0000000000000791","article-title":"Long-Term Topical Ganciclovir and corticosteroids preserve corneal endothelial function in Cytomegalovirus corneal endotheliitis","volume":"35","author":"Fan","year":"2016","journal-title":"Cornea"},{"key":"2025090109363951000_2.1.e000061.20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1442-9071.2012.02888.x","article-title":"Topical ganciclovir treatment in patients with cytomegalovirus endotheliitis receiving penetrating keratoplasty","volume":"41","author":"Su","year":"2013","journal-title":"Clin Exp Ophthalmol"},{"key":"2025090109363951000_2.1.e000061.21","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ajo.2014.08.007","article-title":"Clinical outcomes in cytomegalovirus-positive Posner-Schlossman syndrome patients treated with topical ganciclovir therapy","volume":"158","author":"Su","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"2025090109363951000_2.1.e000061.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"2025090109363951000_2.1.e000061.23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/TCRM.S58242","article-title":"Hong BY: ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications","volume":"10","author":"Chou","year":"2014","journal-title":"The Clin Risk Manag"},{"key":"2025090109363951000_2.1.e000061.24","first-page":"441","article-title":"Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocularherpes","volume":"4","author":"Colin","year":"2007","journal-title":"ClinOphthalmol"},{"key":"2025090109363951000_2.1.e000061.25","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1994.10.439"},{"key":"2025090109363951000_2.1.e000061.26","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.167767"},{"key":"2025090109363951000_2.1.e000061.27","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199039040-00008"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2016-000061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:36:48Z","timestamp":1756744608000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2016-000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,9,7]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1136\/bmjophth-2016-000061"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2016-000061","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}